Mindpeak
Artificial Intelligence-based Solutions for Cancer Diagnostics

The capability of Artificial Intelligence in providing personalized services and accurate predictions is being leveraged across every major industry, but an unprecedented application is rising to popularity in the healthcare sector. Hamburg-based company Mindpeak has developed AI-based solutions that empower pathologists to swiftly and accurately diagnose cancer. Until now, the diagnostics of cancer has been focused on examining tissue samples through microscopes. However, the introduction of AI is significantly improving the diagnostic processes. Mindpeak’s exceptionally efficient and robust solutions generate consistently reliable results for even varying image quality of tissue samples from various labs.

Mindpeak is an AI-based software developer that is bringing precision and convenience into image analysis in clinical pathology. On a mission to make microscopical analysis accessible to healthcare professionals across the globe, the company automates visual processes in clinical laboratories with AI and deep learning algorithms. Mindpeak has partnerships with world-leading pathology labs and universities and consists of a team of seasoned experts in ML and software engineering. The company’s tools are adorned with visual diagnostic capabilities using innovative AI and deep learning algorithms.These tools assist cancer specialists in executing reliable and reproducible cancer diagnoses, eliminating the need to carry out tedious and repetitive tasks and allowing healthcare professionals to focus on tasks where human expertise is quintessential.

Mindpeak’s BreastIHC solution uses AI to detect and quantify breast cancer cells. It is also the world’s first-ever plug-and-play AI-based product specifically designed for reliable Ki-67, estrogen receptor, and progesterone quantification processes. Researchers can perform the operations without having to fine-tune the solutions manually, owing to its AI functionalities. BreastIHC automatically detects and classifies cells into stained and unstained tumor cells, empowering researchers to improve their analytical scoring in the tumor microenvironment. Given that cancer is a multifaced disorder with a plethora of genetic and epigenetic variations, Mindpeak’s AI-based algorithms hold great promise to enhance the identification processes for these genetically mutated and aberrant cells at very stages. BreastIHC was developed to cater to dynamic laboratory scenarios, and hence it is capable of generating highly accurate results even in challenging operations such as slide preparations, imaging, and staining. Considering it is difficult for researchers to jettison their existing systems, potentially disrupting their progress, Mindpeak’s systems are provided with a broad range of scanners and cameras that can easily be integrated into existing workflows. In addition to this, Mindpeak also offers Mindpeak PD-L1 Quantifier that is employed for the detection of lung cancer cells.

The assessment of PD-L1 stained lung tissue is a highly complicated and challenging task, and Mindpeak PD-L1 Quantifier leverages AI to accurately detect and quantify diagnostically relevant lung cancer cells. Mindpeak’s Onychomycosis AI, a unique dermatopathology solution, uses similar algorithms to detect fungus hypha. The company has already developed the systems for millions of users and built them in compliance with local and international regulatory requirements. Modern biomedical research is rapidly evaluating the role of contemporary technologies like AI to improve the operational efficiencies of laboratories. The introduction of AI, ML, and deep learning in the healthcare ecosystems for the detection of cancer is a great leap forward, and Mindpeak is at the forefront of this revolution. The company is pushing the boundaries of innovation and promising outcomes that are truly unprecedented in cancer treatment. Mindpeak’s solutions work efficiently and fulfill the requirements of today’s clinical diagnostics environments.